• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.15% Nasdaq Up0.36%

    Amgen Inc. (AMGN)

    -NasdaqGS
    170.17 Up 1.69(1.00%) 4:00PM EST
    |After Hours : 170.17 Down 0.00 (0.00%) 6:51PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Amgen Inc.
    One Amgen Center Drive
    Thousand Oaks, CA 91320
    United States - Map
    Phone: 805-447-1000
    Fax: 805-447-1010
    Website: http://www.amgen.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:20,000

    Business Summary 

    Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company’s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company’s products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Amgen Inc.

    Corporate Governance 
    Amgen Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 2. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 1; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Mr. Robert A. Bradway , 51
    Chairman, Chief Exec. Officer, Pres, Chairman of Exec. Committee and Member of Equity Award Committee
    5.65M0.00
    Mr. Madhavan Balachandran , 63
    Exec. VP of Operations
    2.57M1.30M
    Dr. Sean E. Harper M.D., 51
    Exec. VP of R&D
    2.66M447.00K
    Mr. Anthony C. Hooper , 59
    Exec. VP of Global Commercial Operations
    2.98M0.00
    Mr. David W. Meline , 57
    Chief Financial Officer and Exec. VP
    N/AN/A
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders